An­a­lysts throw cold wa­ter on Ex­elix­is and Roche's prostate can­cer da­ta, putting the pair a fur­ther step be­hind No­var­tis

Ex­elix­is has block­buster dreams for its Cabome­tyx drug, and it’s look­ing to cap­i­tal­ize in the prostate can­cer mar­ket by com­bin­ing it with Roche’s Tecen­triq. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER